Zenas BioPharma, Inc.: shareholders and insiders

ZBIONASDAQHealthcare · Pharmaceutical Preparations

Price

$23.85

November 20, 2026Market cap $1.6B

What Ploutos Investor adds for Zenas BioPharma

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 3 fiscal years, from 2023
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Nov 22, 2025 to Sep 2, 2026, from their own Form 4 filings.

11 Form 4s

Bought on the market

$11M

4 people

Sold on the market

–

nobody

From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

No sales in the period.

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·bought $11M by 4 people·no sales

  • 2025: no buys, no sales
  • 2026: bought $11M by 4 people, no sales
  • Feb 5, 2026Joseph L FarmerPresident and Chief Operating Officer
    Kind
  • Feb 5, 2026Jennifer A. FoxChief Business Officer and Chief Financial Officer
    Kind
  • May 18, 2026Leon O Moulder JrChief Executive Officer
    Kind
  • Apr 29, 2026Leon O Moulder JrChief Executive Officer
    Kind
  • Apr 28, 2026Leon O Moulder JrChief Executive Officer
    Kind
  • Mar 31, 2026Hongbo Lu
    Kind
  • Mar 31, 2026Tomas Kiselak
    Kind
  • Mar 31, 2026Hongbo Lu
    Kind
  • Mar 31, 2026Leon O Moulder JrChief Executive Officer
    Kind
  • Mar 30, 2026Leon O Moulder JrChief Executive Officer
    Kind
  • Feb 13, 2026Patricia L Allen
    Kind
  • Feb 12, 2026Patricia L Allen
    Kind
  • Feb 12, 2026Patricia L Allen
    Kind
  • Feb 12, 2026Patricia L Allen
    Kind
  • Feb 11, 2026Hongbo Lu
    Kind
  • Feb 2, 2026Leon O Moulder JrChief Executive Officer
    Kind
  • Jan 9, 2026Leon O Moulder JrChief Executive Officer
    Kind
  • Jan 8, 2026Leon O Moulder JrChief Executive Officer
    Kind
  • Jan 7, 2026Leon O Moulder JrChief Executive Officer
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 17, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by ZBIO's officers and directors from 2024 up to November 21, 2025, 2 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

6 Holders over 5%2 On a 13DNov 5, 2026 Latest filing
  • FMRwith 1 more person
    Share of class14.3%
  • InnoCare Pharma Inc.with 2 more persons
    Share of class10.4%
  • Wellington Management Group LLPwith 3 more persons
    Share of class10.1%
  • SR One Capital Management, LLCwith 7 more persons
    Share of class7.70%
  • Moulder Leon O Jrwith 2 more persons
    Share of class5.09%
  • BlackRock, Inc.
    Share of class5.00%

What the holders on a 13D state as their purpose

From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.

  • SR One Capital Management, LLC7.7%From the filing of Oct 14, 2025

    The Funds acquired their respective shares for investment purposes. Depending on market conditions, their continuing evaluation of the business and prospects of the Issuer and other factors, the Funds and other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a…

    From the filing of Oct 14, 2025
  • Moulder Leon O Jr5.1%From the filing of May 5, 2026

    The information set forth in Item 3 of this Statement is incorporated herein by reference. Mr. Moulder serves as the Chairman of the Issuer's Board of Directors and as its Chief Executive Officer. In such capacity, Mr. Moulder has influence over the corporate activities of the Issuer, including activities that may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Except as described herein, the Reporting Persons have no present plans or proposals that relate to or would result in any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. However, the Reporting Persons reserve the right to formulate in the future plans…

    From the filing of May 5, 2026
Fell to 5% or less (4)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • Xencor, Inc.1.50%Nov 5, 202613G/A
  • Enavate Sciences GP, LLC13D4.90%Aug 19, 202613D/A
  • Novo Holdings A/S4.70%Nov 14, 202513G/A
  • Longitude Capital Partners IV, LLC13D4.90%Oct 14, 202513D/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Point72 (Cohen)
    In the quarter+512%
  • Citadel Advisors (Griffin)
    In the quarter
  • Millennium Mgmt (Englander)
    In the quarter-71%
  • AQR Capital
    In the quarter-17%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 18.5% of its shares outstanding were held short, +5.0% since the report before.

Shares held short
12.54M
18.5%
Since the report before11.94M on Sep 30, 2026
+5.0%
18.8
666.1K
More days to cover thanof 4,578 US-listed companies with enough volume
99%
Report date
Oct 15, 2026
  • Sep 30, 2024: Shares held short 230.6K
  • Oct 15, 2024: Shares held short 408.9K
  • Oct 31, 2024: Shares held short 635.7K
  • Nov 15, 2024: Shares held short 799.4K
  • Nov 29, 2024: Shares held short 1.47M
  • Dec 13, 2024: Shares held short 2.13M
  • Dec 31, 2024: Shares held short 3.22M
  • Jan 15, 2025: Shares held short 3.34M
  • Jan 31, 2025: Shares held short 3.30M
  • Feb 14, 2025: Shares held short 3.47M
  • Feb 28, 2025: Shares held short 3.41M
  • Mar 14, 2025: Shares held short 3.74M
  • Mar 31, 2025: Shares held short 3.83M
  • Apr 15, 2025: Shares held short 4.39M
  • Apr 30, 2025: Shares held short 4.87M
  • May 15, 2025: Shares held short 4.92M
  • May 30, 2025: Shares held short 4.86M
  • Jun 13, 2025: Shares held short 4.91M
  • Jun 30, 2025: Shares held short 5.10M
  • Jul 15, 2025: Shares held short 5.07M
  • Jul 31, 2025: Shares held short 5.23M
  • Aug 15, 2025: Shares held short 5.27M
  • Aug 29, 2025: Shares held short 5.76M
  • Sep 15, 2025: Shares held short 5.55M
  • Sep 30, 2025: Shares held short 5.62M
  • Oct 15, 2025: Shares held short 4.34M
  • Oct 31, 2025: Shares held short 4.77M
  • Nov 14, 2025: Shares held short 4.61M
  • Nov 28, 2025: Shares held short 4.86M
  • Dec 15, 2025: Shares held short 4.95M
  • Dec 31, 2025: Shares held short 4.78M
  • Jan 15, 2026: Shares held short 6.09M
  • Jan 30, 2026: Shares held short 6.57M
  • Feb 13, 2026: Shares held short 7.80M
  • Feb 27, 2026: Shares held short 8.02M
  • Mar 13, 2026: Shares held short 7.71M
  • Mar 31, 2026: Shares held short 9.36M
  • Apr 15, 2026: Shares held short 10.22M
  • Apr 30, 2026: Shares held short 10.85M
  • May 15, 2026: Shares held short 10.69M
  • May 29, 2026: Shares held short 10.88M
  • Jun 15, 2026: Shares held short 11.13M
  • Jun 30, 2026: Shares held short 12.20M
  • Jul 15, 2026: Shares held short 12.17M
  • Jul 31, 2026: Shares held short 11.75M
  • Aug 14, 2026: Shares held short 11.66M
  • Aug 31, 2026: Shares held short 11.70M
  • Sep 15, 2026: Shares held short 11.87M
  • Sep 30, 2026: Shares held short 11.94M
  • Oct 15, 2026: Shares held short 12.54M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading67.4% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 67.4% of the shares in the reported trades were short sales, against 61.9% in the 14 before.

Last 14 sessionsNov 3, 2026 – Nov 20, 2026
67.4%
The 14 beforeOct 14, 2026 – Nov 2, 2026
61.9%
Change
+5.5 pts
Short sales a dayon average, of 200.7K shares
135.3K
More than atof 3,666 US-listed companies, same days
95%
Median of alleight in ten from 34.4% to 63.9%
50.5%
  • Oct 14, 2026: Short sales 58.3%
  • Oct 15, 2026: Short sales 34%
  • Oct 16, 2026: Short sales 79.6%
  • Oct 19, 2026: Short sales 76.3%
  • Oct 20, 2026: Short sales 70.8%
  • Oct 21, 2026: Short sales 66.9%
  • Oct 22, 2026: Short sales 55.3%
  • Oct 23, 2026: Short sales 51.8%
  • Oct 26, 2026: Short sales 57.2%
  • Oct 27, 2026: Short sales 70.7%
  • Oct 28, 2026: Short sales 66.9%
  • Oct 29, 2026: Short sales 64%
  • Oct 30, 2026: Short sales 51.1%
  • Nov 2, 2026: Short sales 39.6%
  • Nov 3, 2026: Short sales 45.6%
  • Nov 4, 2026: Short sales 39.5%
  • Nov 5, 2026: Short sales 76%
  • Nov 6, 2026: Short sales 82.4%
  • Nov 9, 2026: Short sales 66.4%
  • Nov 10, 2026: Short sales 77.9%
  • Nov 11, 2026: Short sales 48%
  • Nov 12, 2026: Short sales 64.8%
  • Nov 13, 2026: Short sales 81.3%
  • Nov 16, 2026: Short sales 81.3%
  • Nov 17, 2026: Short sales 72.7%
  • Nov 18, 2026: Short sales 66.6%
  • Nov 19, 2026: Short sales 69.3%
  • Nov 20, 2026: Short sales 82.9%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

15.39M Insiders' shares26.84% Of the company
  • Zebra Aggregator, LPTenPercentOwner
    Directly–
  • Tomas KiselakDirector
    Directly–
  • Peter Evan HarwinDirector
    Directly–
  • Fairmount Funds Management LLCDirector
    Directly–
  • Patrick G EnrightDirector
    Directly12.0K
  • Sr One Capital Management, LlcTenPercentOwner
    Directly–
  • Jason Raleigh NunnDirector
    Directly–
  • Leon O Moulder JrChief Executive Officer
    Directly423.2K
  • Hongbo LuDirector
    Directly–
  • Patricia L AllenDirector
    Directly19.9K
  • Ting XiaoDirector
    Directly10.0K
  • Jennifer A. FoxChief Business Officer and Chief Financial Officer
    Directly1,592
  • Joseph L FarmerPresident and Chief Operating Officer
    Directly974

A lower bound: it counts only the 13 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

17 ETFs holding it0.32% The largest weight (XBI)
  • XBIState Street(R) SPDR(R) S&P(R) Biotech ETF
    Weight in the fund0.32%
  • LABUDirexion Daily S&P Biotech Bull 3X Shares
    Weight in the fund0.29%
  • IWCiShares Micro-Cap ETF
    Weight in the fund0.16%
  • IBBiShares Biotechnology ETF
    Weight in the fund0.06%
  • IWOiShares Russell 2000 Growth ETF
    Weight in the fund0.04%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.03%
  • SCHASchwab U.S. Small-Cap ETF
    Weight in the fund0.03%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.02%
  • FESMFidelity Enhanced Small Cap Core ETF
    Weight in the fund0.02%
  • VHTVanguard Health Care Index Fund
    Weight in the fund0.01%

17 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

145 Managers, Q2 2026$1.5B Value of their positions
  • Q3 2025: Managers 80
  • Q4 2025: Managers 119
  • Q1 2026: Managers 140
  • Q2 2026: Managers 145

Institutional investors by quarter

The fund managers holding ZBIO, quarter by quarter, from Q2 2015 to Q2 2025, 24 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 145 managers held 61.27M shares, worth $1.5B. During the quarter 29 opened a position, 24 closed one, 57 added and 38 trimmed.

The largest holders, Q2 2026

  • FMR
    In the quarter+4.7%
  • SR One Capital Management
    In the quarter
  • NEA Management
    In the quarter
  • Enavate Sciences Gp
    In the quarter
  • Federated Hermes
    In the quarter-0.3%
  • BlackRock
    In the quarter+32%
  • Capital International Investors
    In the quarter+2.8%
  • Polar Capital Holdings
    In the quarter-5.3%
  • Royalty Pharma Sub-Manager
    In the quarter
  • Fairmount Funds Management
    In the quarter

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Zenas BioPharma's filings show?

Who buys and sells is one part of Zenas BioPharma's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about ZBIO's shareholders

Didn't find what you were looking for?

Ask us
Have ZBIO's insiders bought or sold?

From Jun 17, 2026 to Sep 2, 2026 Zenas BioPharma's insiders reported no purchase or sale of shares on the market.

Which well-known managers hold ZBIO?

4 of the managers we track held the shares on Sep 30, 2026. The largest position was Millennium Mgmt (Englander)'s, worth $5.2M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.